Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population

European Journal of Internal Medicine

Volumn 22, Issue 2, 2011, Pages 177-181

  Ascaso, Juan F ^a   Millán, Jesús ^b   Mateo Gallego, Rocio ^c   Ruiz, Antonio ^d   Suarez Tembra, M ^e   Borrallo, Rosa M ^f   Zambon, Daniel ^g   Gonzalez Santos, Pedro ^h   Peres De Juan, Miguel ⁱ   Ros, Emili ^g  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d CS Pinto   (Spain)

^e San Rafael Hospital   (Spain)

^f Terrasa Hospital   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h University Clinic Hospital   (Spain)

ⁱ Unidad de Conductas Adictivas   (Spain)

Author keywords

Cardiovascular disease; Diabetes; Hypertriglyceridemia; Metabolic syndrome

Indexed keywords

GLUCOSE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MEDICAL SOCIETY; METABOLIC SYNDROME X; MULTICENTER STUDY; PREVALENCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; SPAIN;

EID: 79952704415     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.12.011     Document Type: Article

References (26)

1. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007;92:1581-9.
2. Sousa MO, Alia P, Pinto X, Corbella E, Navarro MA. Interaction between APOA5-1131 T>C and APOE polymorphisms and their association with severe hypertriglyceridemia. Clin Chim Acta 2008;395:68-71.
3. Tolosa M, Peiró S, Real JT, Cano A, Ascaso JF, Carmena R. The influence of the apo E phenotypes on the lipidic response to hormonal replacement therapy during the menopause. Maturitas 2001;40:173-81. (Pubitemid 33079177)
4. Real JT, Romero P, Martinez Hervas S, Pedro T, Carmena R, Ascaso JF. Role of atherogenic dyslipidemia in the development of metabolic syndrome. Med Clin Barc 2006;127:321-4. (Pubitemid 44580066)
5. Ascaso JF, Gonzalez-Santos P, Hernandez A, Mangas A, Masana L, Millan J, et al. Management of dyslipidemia in the metabolic syndrome recommendations of the Spanish HDL-forum. Am J Cardiovasc Drugs 2007;7:39-58. (Pubitemid 46698514)
6. Ascaso JF, Martinez-Hervas S. Metabolic syndrome and cardiovascular risk associated. Clin Invest Arterioscl 2009;2:13-7.
7. Triglyceride coronary disease genetics consortium and emerging risk factors collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9.
8. Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk 2000;7:339-45.
9. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-84. (Pubitemid 26186958)
10. Mostaza JM, Pintó X, Valdivielso P, Civeira F, Ascaso J. Registro de hipertrigliceridemias de la Sociedad Española de Arteriosclerosis. Clin Invest Arterioscl 2007;19:303-7.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. DeBacker G, Ambrosini E, Borch-Johnsen K, Brotons C, Cifkova R, Dallangeville J, et al. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
13. Alberti KG, Zimmet P, Shaw J. For the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
14. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
15. Ascaso JF, González-Santos P, Hernández Mijares A, Mangas Rojas A, Masana Marín L, Millán Núñez-Cortés J, et al. Diagnosis of metabolic syndrome. Adaptation of diagnostic criteria in our setting. Recommendations of the HDL forum. Rev Clín Esp 2006;206:576-82.
16. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal adiposity (waist circumference) and its relation to insulin resistance and the metabolic syndrome in a South European Population. Eur J Intern Med 2003;14:101-6. (Pubitemid 36457952)
17. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug treated hypertensive patients and control subjects. J Intern Med 1999;2245:163-74. (Pubitemid 29089113)
18. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. MS and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:666-73. (Pubitemid 41099045)
19. Scuteri A, Najjar SS, Morrell CH, Lakatta EG. Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diab Care 2005;28:882-7. (Pubitemid 40434490)
20. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002;59:809-15.
21. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72. (Pubitemid 43113437)
22. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino Sr RB, Wilson PW. Impact of insulin resistance on risk of Type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diab Care 2007;30:1219-25. (Pubitemid 46684651)
23. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21:52-8.
24. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diab Care 2007;30:8-13.
25. Cameron AJ, Zimmet PC, Soderberg S, Alberti KGMM, Sicree R, Tuomilehto J, et al. The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 2007;24:1460-9. (Pubitemid 350179441)
26. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med Clin Barc 2005;124:606-12. (Pubitemid 40780789)